A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Part of paid clinical trials in Stanford, California.

Sponsor
Pamela L. Kunz
Study ID
NCT00947167
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • pertuzumab — DRUG
    840 mg, 420 mg, iv
  • erlotinib — DRUG
    150 mg, PO

Study Details

To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).

Key Dates

First listed
Jul 27, 2009
Start date
Mar 31, 2009
Status verified
Jan 2017
Primary completion
May 31, 2010
Completion
May 31, 2010

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pertuzumab and Erlotinib

Primary Outcome Measure

Response Rate (RR) for All Patients Treated With This Strategy (Simon Design) [ Time Frame: CT scans are done every 4 cycles (every 12 wks) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By condition
NeuroblastomaNeuroendocrine tumors
By specialty
OncologyPediatric oncology
By research site
Stanford University School of Medicine· Stanford, CA

Related Studies